Taiwan · Delayed Price · Currency is TWD PharmaEngine Statistics
Total Valuation
PharmaEngine has a market cap or net worth of TWD 8.48 billion. The enterprise value is 3.44 billion.
| Market Cap | 8.48B |
| Enterprise Value | 3.44B |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | Aug 17, 2026 |
Share Statistics
PharmaEngine has 143.68 million shares outstanding. The number of shares has decreased by -0.03% in one year.
| Current Share Class | 143.68M |
| Shares Outstanding | 143.68M |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 1.23% |
| Owned by Institutions (%) | 5.79% |
| Float | 93.45M |
Valuation Ratios
The trailing PE ratio is 15.78.
| PE Ratio | 15.78 |
| Forward PE | n/a |
| PS Ratio | 8.27 |
| PB Ratio | 1.73 |
| P/TBV Ratio | 1.73 |
| P/FCF Ratio | 15.69 |
| P/OCF Ratio | 15.68 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.95, with an EV/FCF ratio of 6.37.
| EV / Earnings | 6.39 |
| EV / Sales | 3.36 |
| EV / EBITDA | 6.95 |
| EV / EBIT | 7.10 |
| EV / FCF | 6.37 |
Financial Position
The company has a current ratio of 11.20, with a Debt / Equity ratio of 0.01.
| Current Ratio | 11.20 |
| Quick Ratio | 11.11 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.08 |
| Debt / FCF | 0.07 |
| Interest Coverage | 979.95 |
Financial Efficiency
Return on equity (ROE) is 11.26% and return on invested capital (ROIC) is 21,214.83%.
| Return on Equity (ROE) | 11.26% |
| Return on Assets (ROA) | 5.44% |
| Return on Invested Capital (ROIC) | 21,214.83% |
| Return on Capital Employed (ROCE) | 9.81% |
| Weighted Average Cost of Capital (WACC) | 5.03% |
| Revenue Per Employee | 22.78M |
| Profits Per Employee | 11.97M |
| Employee Count | 45 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 1.71 |
Taxes
In the past 12 months, PharmaEngine has paid 107.74 million in taxes.
| Income Tax | 107.74M |
| Effective Tax Rate | 16.66% |
Stock Price Statistics
The stock price has decreased by -12.33% in the last 52 weeks. The beta is 0.14, so PharmaEngine's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | -12.33% |
| 50-Day Moving Average | 62.11 |
| 200-Day Moving Average | 63.45 |
| Relative Strength Index (RSI) | 39.70 |
| Average Volume (20 Days) | 388,254 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEngine had revenue of TWD 1.03 billion and earned 538.80 million in profits. Earnings per share was 3.74.
| Revenue | 1.03B |
| Gross Profit | 962.23M |
| Operating Income | 485.08M |
| Pretax Income | 646.54M |
| Net Income | 538.80M |
| EBITDA | 487.44M |
| EBIT | 485.08M |
| Earnings Per Share (EPS) | 3.74 |
Balance Sheet
The company has 5.07 billion in cash and 37.78 million in debt, with a net cash position of 5.03 billion or 35.04 per share.
| Cash & Cash Equivalents | 5.07B |
| Total Debt | 37.78M |
| Net Cash | 5.03B |
| Net Cash Per Share | 35.04 |
| Equity (Book Value) | 4.91B |
| Book Value Per Share | 34.07 |
| Working Capital | 4.89B |
Cash Flow
In the last 12 months, operating cash flow was 540.65 million and capital expenditures -339,000, giving a free cash flow of 540.31 million.
| Operating Cash Flow | 540.65M |
| Capital Expenditures | -339,000 |
| Depreciation & Amortization | 2.37M |
| Net Borrowing | -8.69M |
| Free Cash Flow | 540.31M |
| FCF Per Share | 3.76 |
Margins
Gross margin is 93.87%, with operating and profit margins of 47.32% and 52.56%.
| Gross Margin | 93.87% |
| Operating Margin | 47.32% |
| Pretax Margin | 63.07% |
| Profit Margin | 52.56% |
| EBITDA Margin | 47.55% |
| EBIT Margin | 47.32% |
| FCF Margin | 52.71% |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 3.44%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 3.44% |
| Dividend Growth (YoY) | -66.67% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 159.97% |
| Buyback Yield | 0.03% |
| Shareholder Yield | 3.47% |
| Earnings Yield | 6.36% |
| FCF Yield | 6.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2017. It was a forward split with a ratio of 1.1999616012.
| Last Split Date | Jul 26, 2017 |
| Split Type | Forward |
| Split Ratio | 1.1999616012 |
Scores
PharmaEngine has an Altman Z-Score of 13.18 and a Piotroski F-Score of 5.
| Altman Z-Score | 13.18 |
| Piotroski F-Score | 5 |